Finance entity
All 1 tracked stories fall under one category: markets. Of the tracked stories, 1 of 1 also mention 329 Services, the most common co-covered peer. Each story carries 3 original sources on average, compared with 2.4 for the broader beat in this window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: markets. Of the tracked stories, 1 of 1 also mention 329 Services, the most common co-covered peer. Each story carries 3 original sources on average, compared with 2.4 for the broader beat in this window. The 6 average consequence score is below the beat benchmark of 6.2 in the same window. Alto Neuroscience appears in 1 tracked Finance story from March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 119 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alto Neuroscience. Shared-story counts are live from our verified record — not editorial picks.
Alto Neuroscience has successfully raised $120 million through a private placement, a significant capital injection aimed at accelerating its precision psychiatry platform. Led by CFO Nick Smith, the financing highlights growing investor confidence in biomarker-driven approaches to treating central nervous system (CNS) disorders.
Alto Neuroscience is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
